Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells 7,857 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $22.72, for a total value of $178,511.04. Following the completion of the transaction, the insider owned 549,080 shares of the company’s stock, valued at approximately $12,475,097.60. This represents a 1.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.92, for a total value of $311,366.64.
• On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.60, for a total transaction of $202,224.80.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00.
• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.96, for a total value of $314,400.00.

Kestra Medical Technologies Stock Performance

NASDAQ KMTS traded up $1.16 on Monday, reaching $23.99. The stock had a trading volume of 373,728 shares, compared to its average volume of 404,856. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. Kestra Medical Technologies, Ltd. has a 12-month low of $14.10 and a 12-month high of $30.00. The business’s 50-day moving average price is $22.62 and its 200 day moving average price is $22.48. The stock has a market cap of $1.41 billion, a P/E ratio of -9.91 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The business had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. As a group, equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC bought a new position in shares of Kestra Medical Technologies during the fourth quarter worth about $31,000. Russell Investments Group Ltd. boosted its holdings in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after buying an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. bought a new position in Kestra Medical Technologies during the fourth quarter worth about $72,000. Finally, Brown Brothers Harriman & Co. grew its position in shares of Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after purchasing an additional 656 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. BTIG Research lifted their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Oppenheimer started coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, The Goldman Sachs Group decreased their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $27.83.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.